CClinicalTrials.gg
Status unknownNCT03487523Updated Apr 4, 2018

Health Message Framing to Improve Uptake of Bowel Cancer Screening

An interventional study of Text Message in Colorectal Cancer, sponsored by National Heatlh Service Ayrshire and Arran. Status unknown. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-04.

Sponsored by National Heatlh Service Ayrshire and Arran · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

The objective of this research is to investigate whether a text message (SMS message) prompting participation in the UK national bowel cancer screening programme improves uptake for those who have not responded to the test.

The secondary objective is to investigate whether the framing/phrasing of the text message improves participation , whether by stating the benefits of uptake or alternatively by stating the costs of non-uptake.

Read the detailed description

A national register exists for GP practices to identify which patients of theirs have or have not participated in a national bowel cancer screening programme. A sample of 1600 patients belonging to a particular practice in Scotland aged between 50 and 74 have been identified as having received the test kit but have not responded to it. These individuals have also previously consented to being contacted by the practice via phone text/SMS message for reminders.

The sample will be randomised into three equally populated groups:

  • One group will act as the control arm and will receive no text message.
  • One group will receive a text message which encourages participation in the screening programme and provides information on the cost of not participating (negative frame) - "If you do not take part in screening then you increase the risk of having an undiagnosed tumor."
  • One group will receive a text message which encourages participation in the screening programme and provides information on the benefit of participating (positive frame) - "If you take part in screening then you decrease the risk of having an undiagnosed tumor."

Both text messages will include a weblink which will direct individuals receiving the text to find more information and also with instructions on how to order another kit should they have misplaced the kit that was mailed out to them.

The observation period will last 6 months and patients receiving the text will receive 3 texts in total. One at the start of the 6 months and another every two months after that. These messages will not change or alternate, that is the negatively framed group will receive the same text once every 2 months on 3 occasions in total and vice versa. Other studies have used shorter intervals between text messages to encourage change, although 6 months to 1 year is a standard amount of time overall. The researchers feel that while more regular messages may be more likely prompt behaviour there is also a risk of over-burdening the patient with reminders, as such 3 texts over 6 months was decided upon as a reasonable frequency.

At the end of the 6 months data on uptake of screening for those 1600 patients during that time will be extracted by the practice clinician, matched with patient characteristics (e,g, age, sex) and anonymised so that patients cannot be identified. This will then be sent to the health economist to analyse the data and test the hypotheses above. Regression analysis will be used to see whether a differential pattern of uptake exists between groups receiving and not receiving the text message.

Once analysed the results will be fed back to the practice in order to help inform future reminders and will also be drafted into a paper to be submitted for peer-review.

02

Conditions studied

  • Colorectal Cancer

Keywords

  • Behavioural Economics
03

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Over 55
  • Not yet returned a bowel cancer screening sample
  • No diagnosis of bowel cancer

Exclusion criteria

Exclusion Criteria:

  • Under 55
  • Have already completed bowel cancer screening
  • Diagnosed with bowel cancer
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
1,600 participants (estimated)

Study arms

  • Active comparator
    Intervention 1

    Text message (SMS Message)

    Behavioral: Text Message

  • Active comparator
    Intervention 2

    Text message (SMS Message)

    Behavioral: Text Message

  • No intervention
    Intervention 3

    no intervention

Interventions

  • BehavioralText Message

    As already stated

05

What researchers measure

Primary outcomes

  1. Number of participants taking part in the Scottish national bowel cancer screening programme

    Number of participants taking part in the Scottish national bowel cancer screening programme represented as a patient having submitted a faecal occult blood test.

    Time frame: 6 months

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03487523
Lead sponsor
National Heatlh Service Ayrshire and Arran
Responsible party
Patrick McGuire (GP Registrar, National Heatlh Service Ayrshire and Arran) — Principal investigator
First posted
Apr 4, 2018
Start date
Jun 21, 2018 (estimated)
Primary completion
Dec 21, 2018 (estimated)
Completion
Jan 31, 2019 (estimated)
Last update
Apr 4, 2018

Study contacts

Patrick McGuire
Contact
paddymcguire7@gmail.com
+447596096536
Patrick McGuire
principal investigator · Dr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion